Hoping to follow the one Australian and three U.S. biotechs that have managed to go public this year, French immunotherapy firm Neovacs SA is seeking to raise about €20 million (US$27 million) and boost its profile with a listing on the Alternext Exchange in Paris. (BioWorld Today) Assistant Managing Editor Read More